

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

HOSPIRA, INC., and  
SAMSUNG BIOEPIS CO., LTD.,<sup>1</sup>  
Petitioners,

v.

GENENTECH, INC.,  
Patent Owner,

---

Case IPR2017-00805  
Patent 7,371,379

---

**DECLARATION OF CHRISTOPHER LOWDEN**

---

<sup>1</sup> Samsung Bioepis Co. Ltd. has been added as a party to this proceeding following the Board's decision to grant Motion for Joinder in IPR2017-01959. Paper 9 (IPR2017-01959).

I, Christopher Lowden, declare under penalty of perjury as follows:

## **I. INTRODUCTION**

1. I am an Electronic Services Librarian at Kirkland & Ellis LLP.

2. I make this Declaration in support of Petitioners' Reply to Patent Owner Genentech's Response. I have previously submitted a declaration in this proceeding. Ex. 1031.

## **II. QUALIFICATIONS**

3. I obtained a Masters in Library Science from the University of Pittsburgh in 1994. In connection with that degree, I took three courses in cataloging: a general cataloging course, and advanced courses in bibliographic description and subject analysis.

4. From 1995 to 1998, I worked as a cataloger at New York University Library. As part of my job duties at New York University, I created and maintained bibliographic records for books and electronic resources at the library. From 1998 to 2001, I was a research analyst for Goodrich & Sherwood. From 2002 to 2005, I worked as a research librarian at Wachtell, Lipton, Rosen & Katz, performing research for attorneys. From 2005 to 2012, I worked as a research librarian at Dewey & Leboeuf, performing research for attorneys.

5. From 2012 to today, I have been an Electronic Services Librarian at Kirkland & Ellis LLP, and I am currently employed by Kirkland & Ellis LLP. I manage the firm's commercial database and news subscriptions, and am personally involved in maintaining the catalog for the Kirkland & Ellis LLP library.

6. Through my education and experience described above, I have interacted with and become personally familiar with the Library of Congress and its cataloging records. The Library of Congress is a research library for the United States Congress. Based on my knowledge and experience, it is the national library of the United States and the most authoritative resource in the United States for library cataloging records. I have used and am familiar with the Library of Congress's online catalog, including through performing searches on the online catalog to find information about the availability of books and other references. The Library of Congress also maintains the United States Copyright Office catalog, which records the registration of copyrighted material. Similarly, the British Library is an authoritative resource for library records and I am familiar with its online catalogue.

### **III. EXHIBITS**

7. Exhibit 1041 is a true and correct copy of Houts, et al., *Nonmedical Costs to Patients and Their Families Associated with Outpatient Chemotherapy*, 53(11) CANCER 2388–92 (1984). Exhibit 1060 is a true and correct copy of the

Library of Congress Copyright Record for the journal Cancer, a record which I obtained from the Library of Congress online catalog located at <http://catalog.loc.gov> on March 6, 2018. In that record, the publication date of Vol. 53, no. 11 is May 15, 1984.

8. Exhibit 1047 is a true and correct copy of Leyland-Jones, *et al.*, *Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination with Paclitaxel*, 21(21) J. CLINICAL ONCOLOGY 3965–71 (2003). Exhibit 1061 is a true and correct copy of the Library of Congress Copyright Record for the Journal of Clinical Oncology, a record which I obtained from the Library of Congress online catalog located at <http://catalog.loc.gov> on March 6, 2018. In that record, the publication date of Vol. 21, no. 21 is November 1, 2003.

9. Exhibit 1050 is a true and correct copy of Mackey, *et al.*, *Adjuvant Targeted Therapy in Early Breast Cancer*, 115(6) CANCER 1154–68 (2009). Exhibit 1062 is a true and correct copy of the Library of Congress Copyright Record for the journal Cancer, a record which I obtained from the Library of Congress online catalog located at <http://catalog.loc.gov> on March 6, 2018. In that record, the publication date of Vol. 115, no. 6 is March 9, 2009.

10. Exhibit 1052 is a true and correct copy of Levy, *Pharmacologic Target-mediated Drug Disposition*, 56(3) CLINICAL PHARMACOLOGY & THERAPEUTICS 248–52 (1994). Exhibit 1063 is a true and correct copy of the Library

of Congress Copyright Record for the journal Clinical Pharmacology & Therapeutics, a record which I obtained from the Library of Congress online catalog located at <http://catalog.loc.gov> on March 6, 2018. In that record, the publication date of Vol. 56, no. 3 is October 3, 1994.


11. Exhibit 1054 is a true and correct copy of Koizumi, *et al.*, *Multicompartmental Analysis of the Kinetics of Radioiodinated Monoclonal Antibody in Patients with Cancer*, 27(8) J. NUCLEAR MED. 1243–54 (1986). Exhibit 1064 is a true and correct copy of the Library of Congress Copyright Record for the Journal of Nuclear Medicine, a record which I obtained from the Library of Congress online catalog located at <http://catalog.loc.gov> on March 6, 2018. In that record, the publication date of Vol. 27, no. 8 is July 30, 1986.

12. Exhibit 1043 is a true and correct copy of Leyland Jones, *Pharmacological Insights into the Future of Herceptin®* (Nov. 1999), in HER2 STATE-OF-THE-ART CONFERENCE REPORT: 21–23 NOVEMBER 1999, LE MONTREAX PALACE HOTEL (2000) (the “HER2 State-of-the-Art Conference Report”). Exhibit 1065 is a true and correct copy of the British Library Catalogue Record for the HER2 State-of-the-Art Conference Report. In that record, the date that the HER2 State-of-the-Art Conference Report was entered into the British Library Catalogue is April 4, 2000, shown in field 008.

#### IV. CONCLUSION

13. I declare under penalty of perjury under the laws of the United States of America that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code.

Executed on March 21, 2018, in New York, New York.

  
Christopher Lowden